MTEM - Molecular Templates

-

$undefined

N/A

(N/A)

Molecular Templates OTC Markets EXMKT:MTEM Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. On April 20, 2025, Molecular Templates, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Location: 9301 Amberglen Boulevard, Austin, TX, 78729, United States | Website: https://www.mtem.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.371M

Cash

9.657M

Avg Qtr Burn

-5.981M

Short % of Float

5.26%

Insider Ownership

3.96%

Institutional Own.

13.25%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MT-6402 Details
Solid tumor/s, Cancer

Phase 1

Data readout

MT-8421 Details
Cancer, Solid tumor/s

Phase 1

Data readout

MT-0169 Details
Hematologic malignancies

Phase 1

Initiation

MT-0169 (TAK-169) (CD38) Details
Multiple myeloma, Extramedullary myeloma

Failed

Discontinued

MT-3724 (CD20) monotherapy Details
DLBCL (Diffuse large B-cell lymphoma)

Failed

Discontinued

MT-3724 (CD20) with Lenalidomide Details
DLBCL (Diffuse large B-cell lymphoma)

Failed

Discontinued

MT-5111 Details
Breast cancer, Cancer

Failed

Discontinued

MT-3724 with GEMOX (CD20) Details
DLBCL (Diffuse large B-cell lymphoma)

Failed

Discontinued